Contact, publication, and social network information about Harvard faculty and fellows. Harvard Catalyst Profiles
Keywords
Last Name
Institution

Elizabeth Bernier Lamont, M.D.

TitleAssociate Professor of Medicine
InstitutionMassachusetts General Hospital
DepartmentMedicine
AddressHarvard Medical School
Health Care Policy
180 Longwood Ave
Boston MA 02115
Phone617/432-4465
Other Positions
TitleAssociate Professor of Health Care Policy
InstitutionHarvard Medical School
DepartmentHealth Care Policy

TitleAssistant Professor of Health Care Policy
InstitutionHarvard Medical School
DepartmentHealth Care Policy


 Bibliographic 
 selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Meilleur A, Subramanian SV, Plascak JJ, Fisher JL, Paskett ED, Lamont EB. Rural residence and cancer outcomes in the United States: issues and challenges. Cancer Epidemiol Biomarkers Prev. 2013 Oct; 22(10):1657-67.
    View in: PubMed
  2. Keating NL, Landrum MB, Lamont EB, Bozeman SR, Shulman LN, McNeil BJ. Tumor boards and the quality of cancer care. J Natl Cancer Inst. 2013 Jan 16; 105(2):113-21.
    View in: PubMed
  3. Lennes IT, Temel JS, Hoedt C, Meilleur A, Lamont EB. Predictors of newly diagnosed cancer patients' understanding of the goals of their care at initiation of chemotherapy. Cancer. 2013 Feb 1; 119(3):691-9.
    View in: PubMed
  4. Lamont EB, He Y, Subramanian SV, Zaslavsky AM. Do socially deprived urban areas have lesser supplies of cancer care services? J Clin Oncol. 2012 Sep 10; 30(26):3250-7.
    View in: PubMed
  5. Soerjomataram I, Thong MS, Ezzati M, Lamont EB, Nusselder WJ, van de Poll-Franse LV. Most colorectal cancer survivors live a large proportion of their remaining life in good health. Cancer Causes Control. 2012 Sep; 23(9):1421-8.
    View in: PubMed
  6. Keating NL, Landrum MB, Lamont EB, Bozeman SR, McNeil BJ. Area-level variations in cancer care and outcomes. Med Care. 2012 May; 50(5):366-73.
    View in: PubMed
  7. Landrum MB, Keating NL, Lamont EB, Bozeman SR, Krasnow SH, Shulman L, Brown JR, Earle CC, Rabin M, McNeil BJ. Survival of older patients with cancer in the Veterans Health Administration versus fee-for-service Medicare. J Clin Oncol. 2012 Apr 1; 30(10):1072-9.
    View in: PubMed
  8. Nambudiri VE, Landrum MB, Lamont EB, McNeil BJ, Bozeman SR, Freedland SJ, Keating NL. Understanding variation in primary prostate cancer treatment within the Veterans Health Administration. Urology. 2012 Mar; 79(3):537-45.
    View in: PubMed
  9. Landrum MB, Keating NL, Lamont EB, Bozeman SR, McNeil BJ. Reasons for underuse of recommended therapies for colorectal and lung cancer in the Veterans Health Administration. Cancer. 2012 Jul 1; 118(13):3345-55.
    View in: PubMed
  10. Kouri EM, Landrum MB, Lamont EB, Bozeman S, McNeil BJ, Keating NL. Location of cancer surgery for older veterans with cancer. Health Serv Res. 2012 Apr; 47(2):783-93.
    View in: PubMed
  11. Gray SW, Landrum MB, Lamont EB, McNeil BJ, Jaklitsch MT, Keating NL. Improved outcomes associated with higher surgery rates for older patients with early stage nonsmall cell lung cancer. Cancer. 2012 Mar 1; 118(5):1404-11.
    View in: PubMed
  12. Keating NL, Landrum MB, Lamont EB, Bozeman SR, Krasnow SH, Shulman LN, Brown JR, Earle CC, Oh WK, Rabin M, McNeil BJ. Quality of care for older patients with cancer in the Veterans Health Administration versus the private sector: a cohort study. Ann Intern Med. 2011 Jun 7; 154(11):727-36.
    View in: PubMed
  13. Keating NL, Landrum MB, Lamont EB, Earle CC, Bozeman SR, McNeil BJ. End-of-life care for older cancer patients in the Veterans Health Administration versus the private sector. Cancer. 2010 Aug 1; 116(15):3732-9.
    View in: PubMed
  14. Oh WK, Landrum MB, Lamont EB, McNeil BJ, Keating NL. Does oral antiandrogen use before leuteinizing hormone-releasing hormone therapy in patients with metastatic prostate cancer prevent clinical consequences of a testosterone flare? Urology. 2010 Mar; 75(3):642-7.
    View in: PubMed
  15. Lamont EB, Landrum MB, Keating NL, Archer L, Lan L, Strauss GM, Lilenbaum R, Niell HB, Maurer LH, Kosty MP, Miller AA, Clamon GH, Elias AD, McClay EF, Vokes EE, McNeil BJ. Differences in clinical trial patient attributes and outcomes according to enrollment setting. J Clin Oncol. 2010 Jan 10; 28(2):215-21.
    View in: PubMed
  16. Dow LA, Matsuyama RK, Ramakrishnan V, Kuhn L, Lamont EB, Lyckholm L, Smith TJ. Paradoxes in advance care planning: the complex relationship of oncology patients, their physicians, and advance medical directives. J Clin Oncol. 2010 Jan 10; 28(2):299-304.
    View in: PubMed
  17. Eichler AF, Lamont EB. Utility of administrative claims data for the study of brain metastases: a validation study. J Neurooncol. 2009 Dec; 95(3):427-31.
    View in: PubMed
  18. Lamont, EB. Physician Estimates of Prognosis. Encyclopedia of Medical Decision Making. In Kattan MW, ed. 2009.
  19. Lamont EB, Dias LE. Secular changes in NSAID use and invasive colorectal cancer incidence: an ecological study. Cancer J. 2008 Jul-Aug; 14(4):276-7.
    View in: PubMed
  20. Lamont EB, Dias LE. Secular changes in NSAID use and invasive colorectal cancer incidence: an ecological study. The Cancer Journal. 2008; 14(4):276-7.
  21. Warren JL, Yabroff KR, Meekins A, Topor M, Lamont EB, Brown ML. Evaluation of trends in the cost of initial cancer treatment. J Natl Cancer Inst. 2008 Jun 18; 100(12):888-97.
    View in: PubMed
  22. Lamont EB. Foreseeing: Formulating An Accurate Prognosis. Prognosis in Advanced Cancer, Glare PA, and Christakis NA (eds). 2008.
  23. Yabroff KR, Lamont EB, Mariotto A, Warren JL, Topor M, Meekins A, Brown ML. Cost of care for elderly cancer patients in the United States. J Natl Cancer Inst. 2008 May 7; 100(9):630-41.
    View in: PubMed
  24. Lamont EB, Herndon JE, Weeks JC, Henderson IC, Lilenbaum R, Schilsky RL, Christakis NA. Measuring clinically significant chemotherapy-related toxicities using Medicare claims from Cancer and Leukemia Group B (CALGB) trial participants. Med Care. 2008 Mar; 46(3):303-8.
    View in: PubMed
  25. EB Lamont, L Archer, L Lan, GM Strauss, R Lilenbaum, HB Niell, LH Maurer, MP Kosty, AA Miller, GH Clamon, AD Elias, EF McClay, EE Vokes, BJ McNeil, NL Keating, and ME Landrum for the Cancer and Leukemia Group B. Differences in Clinical Trial Patients Attributes and Outcomes According to Enrollment Setting. Program Procedings of the American Society of Clinical Oncology. 2008.
  26. Lamont EB, Dias LE, Lauderdale DS. NSAIDs and colorectal cancer risk: do administrative data support a chemopreventive effect? J Gen Intern Med. 2007 Aug; 22(8):1166-71.
    View in: PubMed
  27. Yabroff KR, Davis WW, Lamont EB, Fahey A, Topor M, Brown ML, Warren JL. Patient time costs associated with cancer care. J Natl Cancer Inst. 2007 Jan 3; 99(1):14-23.
    View in: PubMed
  28. EB Lamont, JE Herndon, JC Weeks, IC Henderson, R Lilenbaum, RL Schilsky, and NA Christakis for the Cancer and Leukemia Group B. Measuring Clinically Significant Chemotherapy-Related Toxicity Using Medicare Claims From CALGB Trial Participants. Program Procedings of the American Society of Clinical Oncology. 2007.
  29. Lamont, EB, Christakis NA. Epidemiology and Prognostication in Advanced Cancer. Principle and Practice of Palliative Care and Supportive Oncology, Berger A, Von Roenn J, and Shuster J (eds). 2006.
  30. Lamont EB, Herndon JE, Weeks JC, Henderson IC, Earle CC, Schilsky RL, Christakis NA. Measuring disease-free survival and cancer relapse using Medicare claims from CALGB breast cancer trial participants (companion to 9344). J Natl Cancer Inst. 2006 Sep 20; 98(18):1335-8.
    View in: PubMed
  31. EB Lamont, LE Dias. NSAIDs, osteoarthritis, and colorectal cancer risk: Can administrative data provide a window into the effectiveness of a cancer prevention?. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. 2006: 8572. 2006; 24(18S):1022.
  32. LE Dias, EB Lamont. Academic oncologists' attitudes and practices regarding the care of cancer patients at the end of life. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. 2006: 8572. 2006; 24(18S):8572.
  33. Paskett ED, Schrag D, Kornblith A, Lamont EB, Weeks JC, Marshall JR, Shapiro C, Holland J. Cancer and leukemia group B cancer control and health outcomes committee: origins and accomplishments. Clin Cancer Res. 2006 Jun 1; 12(11 Pt 2):3601s-5s.
    View in: PubMed
  34. Polite BN, Lamont EB. Are venous thromboembolic events associated with subsequent breast and colorectal carcinoma diagnoses in the elderly? A case-control study of Medicare beneficiaries. Cancer. 2006 Feb 15; 106(4):923-30.
    View in: PubMed
  35. Lamont EB, Herndon JE, Weeks JC, Henderson IC, Lilenbaum R, Schilsky RL, Christakis NA. Criterion validity of Medicare chemotherapy claims in Cancer and Leukemia Group B breast and lung cancer trial participants. J Natl Cancer Inst. 2005 Jul 20; 97(14):1080-3.
    View in: PubMed
  36. Lamont EB, Hoffman PH. . The oncologic emergencies. Principles of Critical Care, Hall JB, Schmidt GA, Wood LH (eds). 2005.
  37. Hotte SJ, Winquist EW, Lamont E, MacKenzie M, Vokes E, Chen EX, Brown S, Pond GR, Murgo A, Siu LL. Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study. J Clin Oncol. 2005 Jan 20; 23(3):585-90.
    View in: PubMed
  38. Hotte SJ, Winquist EW, Lamont EB, MacKenzie M, Vokes E, Chen EX, Brown S, Pond GR, Murgo A, Siu LL. Imatinib mesylate in patients with C-Kit expressing adenoid cystic cancer of the salivary glands: a Princess Margaret Hospital phase II consortium study. Journal of Clinical Oncology. 2005; 23 :585-590.
  39. Lamont EB. How to prognosticate in patients with advanced cancer: CME module for End of Life Curriculum Project, Palo Alto VA. 2005.
  40. EB Lamont, JE Herndon, JC Weeks, IC Henderson, R Lilenbaum, RL Schilsky, and NA Christakis for the Cancer and Leukemia Group B. Criterion Validity of Medicare Chemotherapy Claims In Breast and Lung Cancer Patients . Program Procedings of the American Society of Clinical Oncology. 2005.
  41. Lamont EB. A demographic and prognostic approach to defining the end of life. J Palliat Med. 2005; 8 Suppl 1:S12-21.
    View in: PubMed
  42. Improving End-of-Life Care. NIH Consens State Sci Statements. 2004; 21(3):1-28.
  43. Gupta SK, Lamont EB. Patterns of presentation, diagnosis, and treatment in older patients with colon cancer and comorbid dementia. J Am Geriatr Soc. 2004 Oct; 52(10):1681-7.
    View in: PubMed
  44. Lamont EB. Poor prognosis. 2004.
  45. Lamont EB, Lauderdale DS. Low risk of hip fracture among elderly breast cancer survivors. Ann Epidemiol. 2003 Nov; 13(10):698-703.
    View in: PubMed
  46. Lamont EB, Hayreh D, Pickett KE, Dignam JJ, List MA, Stenson KM, Haraf DJ, Brockstein BE, Sellergren SA, Vokes EE. Is patient travel distance associated with survival on phase II clinical trials in oncology? J Natl Cancer Inst. 2003 Sep 17; 95(18):1370-5.
    View in: PubMed
  47. Lamont EB, Christakis NA. Complexities in prognostication in advanced cancer: "to help them live their lives the way they want to". JAMA. 2003 Jul 2; 290(1):98-104.
    View in: PubMed
  48. Lamont EB, Christakis NA, Lauderdale DS. Favorable cardiac risk among elderly breast carcinoma survivors. Cancer. 2003 Jul 1; 98(1):2-10.
    View in: PubMed
  49. SK Gupta, EB Lamont. Patterns of presentation, treatment, and survival in older patients with colon cancer and comorbid dementia. Proceedings of American Society of Clinical Oncology. 2003; 22:529.
  50. EEW Cohen, K Stenson, DM Gustin, E Lamont, AM Mauer, E Blair, WM Stadler, A Dekker, W Mallon, EE Vokes. A phase II study of 250 mg gefitinib (ZD1839) monotherapy in recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). Proceedings of American Society of Clinical Oncology. 2003; 22:502.
  51. EB Lamont, Hayreh D, Pickett KE, Dignam J, List MA, Stenson K, Haraf DJ, Brockstein BE, Vokes EE. Is travel distance associated with survival on phase II clinical trials in oncology?. Proceedings of American Society of Clinical Oncology. 2003; 22:521.
  52. MT Milano, EE Vokes, ME Witt, A Dekker, M List, RD Williams, EB Lamont, RR Weichselbaum, DJ Haraf. Retrospective comparison of intensity modulated radiation therapy (IMRT) and convential three-demensional RT (3DCRT) in advanced head and neck patients treated with definitive chemoradiation. Proceedings of American Society of Clinical Oncology. 2003; 22:499.
  53. E Winquist, E Lamont, S Hotte, M Mackenzie, S Brown, A Murgo, L Siu. Phase II study of imatinib mesylate in patients with adenoid cystic salivary gland carcinoma (ACC). Proceedings of American Society of Clinical Oncology. 2003; 22:513.
  54. Iwashyna TJ, Lamont EB. Effectiveness of adjuvant fluorouracil in clinical practice: a population-based cohort study of elderly patients with stage III colon cancer. J Clin Oncol. 2002 Oct 1; 20(19):3992-8.
    View in: PubMed
  55. Lamont EB, Christakis NA. Physician factors in the timing of cancer patient referral to hospice palliative care. Cancer. 2002 May 15; 94(10):2733-7.
    View in: PubMed
  56. Lamont EB, Lauderdale DS, Schilsky RL, Christakis NA. Construct validity of medicare chemotherapy claims: the case of 5FU. Med Care. 2002 Mar; 40(3):201-11.
    View in: PubMed
  57. EB Lamont, N Christakis, D Lauderdale. Favorable cardiovascular risk in elderly breast cancer survivors. Proceedings of American Society of Clinical Oncology. 2002; 21(part 1):249a.
  58. Lamont EB, Christakis NA. Prognostication in advanced disease. Principles and Practice of Palliative Care and Supportive Oncology, Berger A, Portenoy RK, Weissman DE (eds). 2002.
  59. Lamont EB, Christakis NA. . Survival estimates in advanced cancer. UpToDate (versions 10.2-10.3), Rose BD (ed). 2002.
  60. Lamont EB, Rudin CM, Hoffman PH. . The diagnosis and management of oncologic emergencies. Oncologic Therapies, Golomb HG, Vokes EE (eds). 2002.
  61. Lamont EB, Christakis NA. Survival estimates in advanced cancer. 2002.
  62. EEW Cohen, F Rosen, A Dekker, C Bajda, K Stenson, KL Shulman, E Lamont, M Kozloff, EE Vokes. Phase II study of ZD1839(Iressa) in recurrent and metastatic squamous cell carcinoma of the head and neck (SCCHN). Proceedings of American Society of Clinical Oncology. 2002; 21(Part 1):225a.
  63. Lamont EB, Christakis NA. Prognostic disclosure to patients with cancer near the end of life. Ann Intern Med. 2001 Jun 19; 134(12):1096-105.
    View in: PubMed
  64. Lamont EB, Vokes EE. Chemotherapy in the management of squamous-cell carcinoma of the head and neck. Lancet Oncol. 2001 May; 2(5):261-9.
    View in: PubMed
  65. EB Lamont, N Christakis. Physician factors in the timing of cancer patient referral to hospice. Proceedings of American Society of Clinical Oncology. 2001; 20(Part 1):240a.
  66. Christakis NA, Lamont EB. Extent and determinants of error in physicians' prognoses in terminally ill patients: prospective cohort study. West J Med. 2000 May; 172(5):310-3.
    View in: PubMed
  67. Christakis NA, Lamont EB. Extent and determinants of error in doctors' prognoses in terminally ill patients: prospective cohort study. BMJ. 2000 Feb 19; 320(7233):469-72.
    View in: PubMed
  68. EB Lamont, NA Christakis. Physicians' preferences for prognostic disclosure to cancer patients near the end of life. Proceedings of American Society of Clinical Oncology. 2000; 19:435a.
  69. Lamont EB, Siegler M. Paradoxes in cancer patients' advance care planning. J Palliat Med. 2000; 3(1):27-35.
    View in: PubMed
  70. Lamont EB, Schilsky RL. The oral fluoropyrimidines in cancer chemotherapy. Clin Cancer Res. 1999 Sep; 5(9):2289-96.
    View in: PubMed
  71. Lamont EB, Christakis NA. Some elements of prognosis in terminal cancer. Oncology (Williston Park). 1999 Aug; 13(8):1165-70; discussion 1172-4, 1179-80.
    View in: PubMed
  72. Lamont EB, Schilsky RL . Gonadal toxicity and teratogenicity after cytotoxic chemotherapy. Anticancer Drug Toxicity, Lipp HP (ed). 1999.
  73. Lamont EB, Cavaghan MK, Brockstein BE. Oncogenic osteomalacia as a harbinger of recurrent osteosarcoma. Sarcoma. 1999; 3(2):95-9.
    View in: PubMed
  74. EB Lamont, M Siegler. With whom do oncology inpatients discuss advanced care planning and why?. Proceedings of American Society of Clinical Oncology. 1998; 17:423a.
  75. Lamont EB, Hoffman PC. The diagnosis and management of oncologic emergencies. Oncologic Therapies, Golomb HG, Vokes EE (eds). 1998; 211-127.
  76. Lamont EB, Sayah A. An occult cause of persistent nausea and vomiting. J Emerg Med. 1997 Sep-Oct; 15(5):633-5.
    View in: PubMed
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact Human Resources at faculty_serviceshms.harvard.edu.
Lamont's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts
_
Co-Authors
_
Similar People
_
Same Department
Physical Neighbors
_